Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study

W. C. Koller, G. A. Block, J. E. Ahlskog, S. Ahrens, J. M. Cedarbaum, G. Cyhan, C. G. Goetz, P. A. LeWitt, C. Liss, L. McLean, H. Moses, M. D. Muenter, P. Nausieda, J. Sanchez-Ramos, S. Reich, Carlos Singer, S. Stellar, W. J. Weiner

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458 [hydroxypropyl methylcellulose/lactose matrix (HPMC)], a sustained release formulation of a novel naphthoxazine compound with selective D-2 dopamine receptor agonism. Patients were previously untreated with dopaminergic drugs. Efficacy was assessed by clinical rating scales and by patient self-evaluation. MK-458 (HPMC) caused a significant decrease in most parkinsonian symptoms. Though disability rating scores were lowered by the drug, the scores did not differ significantly from placebo. However, statistically significant improvement occurred with MK-458 (HPMC) on both the physician and the patient global assessments. Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo. MK-458 (HPMC) possesses antiparkinsonian efficacy in early Parkinson's disease; however, side-effects are frequently associated with its use. Selective D-2 receptor agonists, such as MK-458 (HPMC), may not be the ideal treatment as monotherapy for Parkinson's disease.

Original languageEnglish
Pages (from-to)322-329
Number of pages8
JournalClinical Neuropharmacology
Volume14
Issue number4
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Dopamine Agents
Lactose
Multicenter Studies
Parkinson Disease
Placebos
Antiparkinson Agents
Confusion
Diagnostic Self Evaluation
Hallucinations
Dopamine Receptors
Nausea
Vomiting
MK 458
Hypromellose Derivatives
Physicians
Pharmaceutical Preparations

Keywords

  • MK-458
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Koller, W. C., Block, G. A., Ahlskog, J. E., Ahrens, S., Cedarbaum, J. M., Cyhan, G., ... Weiner, W. J. (1991). Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study. Clinical Neuropharmacology, 14(4), 322-329.

Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study. / Koller, W. C.; Block, G. A.; Ahlskog, J. E.; Ahrens, S.; Cedarbaum, J. M.; Cyhan, G.; Goetz, C. G.; LeWitt, P. A.; Liss, C.; McLean, L.; Moses, H.; Muenter, M. D.; Nausieda, P.; Sanchez-Ramos, J.; Reich, S.; Singer, Carlos; Stellar, S.; Weiner, W. J.

In: Clinical Neuropharmacology, Vol. 14, No. 4, 01.01.1991, p. 322-329.

Research output: Contribution to journalArticle

Koller, WC, Block, GA, Ahlskog, JE, Ahrens, S, Cedarbaum, JM, Cyhan, G, Goetz, CG, LeWitt, PA, Liss, C, McLean, L, Moses, H, Muenter, MD, Nausieda, P, Sanchez-Ramos, J, Reich, S, Singer, C, Stellar, S & Weiner, WJ 1991, 'Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study', Clinical Neuropharmacology, vol. 14, no. 4, pp. 322-329.
Koller, W. C. ; Block, G. A. ; Ahlskog, J. E. ; Ahrens, S. ; Cedarbaum, J. M. ; Cyhan, G. ; Goetz, C. G. ; LeWitt, P. A. ; Liss, C. ; McLean, L. ; Moses, H. ; Muenter, M. D. ; Nausieda, P. ; Sanchez-Ramos, J. ; Reich, S. ; Singer, Carlos ; Stellar, S. ; Weiner, W. J. / Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study. In: Clinical Neuropharmacology. 1991 ; Vol. 14, No. 4. pp. 322-329.
@article{90d26cf9216e4ccbb867955ce1e62cd8,
title = "Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study",
abstract = "Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458 [hydroxypropyl methylcellulose/lactose matrix (HPMC)], a sustained release formulation of a novel naphthoxazine compound with selective D-2 dopamine receptor agonism. Patients were previously untreated with dopaminergic drugs. Efficacy was assessed by clinical rating scales and by patient self-evaluation. MK-458 (HPMC) caused a significant decrease in most parkinsonian symptoms. Though disability rating scores were lowered by the drug, the scores did not differ significantly from placebo. However, statistically significant improvement occurred with MK-458 (HPMC) on both the physician and the patient global assessments. Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo. MK-458 (HPMC) possesses antiparkinsonian efficacy in early Parkinson's disease; however, side-effects are frequently associated with its use. Selective D-2 receptor agonists, such as MK-458 (HPMC), may not be the ideal treatment as monotherapy for Parkinson's disease.",
keywords = "MK-458, Parkinson's disease",
author = "Koller, {W. C.} and Block, {G. A.} and Ahlskog, {J. E.} and S. Ahrens and Cedarbaum, {J. M.} and G. Cyhan and Goetz, {C. G.} and LeWitt, {P. A.} and C. Liss and L. McLean and H. Moses and Muenter, {M. D.} and P. Nausieda and J. Sanchez-Ramos and S. Reich and Carlos Singer and S. Stellar and Weiner, {W. J.}",
year = "1991",
month = "1",
day = "1",
language = "English",
volume = "14",
pages = "322--329",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study

AU - Koller, W. C.

AU - Block, G. A.

AU - Ahlskog, J. E.

AU - Ahrens, S.

AU - Cedarbaum, J. M.

AU - Cyhan, G.

AU - Goetz, C. G.

AU - LeWitt, P. A.

AU - Liss, C.

AU - McLean, L.

AU - Moses, H.

AU - Muenter, M. D.

AU - Nausieda, P.

AU - Sanchez-Ramos, J.

AU - Reich, S.

AU - Singer, Carlos

AU - Stellar, S.

AU - Weiner, W. J.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458 [hydroxypropyl methylcellulose/lactose matrix (HPMC)], a sustained release formulation of a novel naphthoxazine compound with selective D-2 dopamine receptor agonism. Patients were previously untreated with dopaminergic drugs. Efficacy was assessed by clinical rating scales and by patient self-evaluation. MK-458 (HPMC) caused a significant decrease in most parkinsonian symptoms. Though disability rating scores were lowered by the drug, the scores did not differ significantly from placebo. However, statistically significant improvement occurred with MK-458 (HPMC) on both the physician and the patient global assessments. Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo. MK-458 (HPMC) possesses antiparkinsonian efficacy in early Parkinson's disease; however, side-effects are frequently associated with its use. Selective D-2 receptor agonists, such as MK-458 (HPMC), may not be the ideal treatment as monotherapy for Parkinson's disease.

AB - Ninety-four patients with early Parkinson's disease were investigated in a double-blind, placebo-controlled evaluation of MK-458 [hydroxypropyl methylcellulose/lactose matrix (HPMC)], a sustained release formulation of a novel naphthoxazine compound with selective D-2 dopamine receptor agonism. Patients were previously untreated with dopaminergic drugs. Efficacy was assessed by clinical rating scales and by patient self-evaluation. MK-458 (HPMC) caused a significant decrease in most parkinsonian symptoms. Though disability rating scores were lowered by the drug, the scores did not differ significantly from placebo. However, statistically significant improvement occurred with MK-458 (HPMC) on both the physician and the patient global assessments. Adverse reactions such as nausea and vomiting, sedation, confusion, and hallucinations occurred more with MK-458 (HPMC) than with placebo. MK-458 (HPMC) possesses antiparkinsonian efficacy in early Parkinson's disease; however, side-effects are frequently associated with its use. Selective D-2 receptor agonists, such as MK-458 (HPMC), may not be the ideal treatment as monotherapy for Parkinson's disease.

KW - MK-458

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0025771274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025771274&partnerID=8YFLogxK

M3 - Article

C2 - 1913699

AN - SCOPUS:0025771274

VL - 14

SP - 322

EP - 329

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 4

ER -